GlassScriptPhysician profile
Holley Leona Davis
NPI 1407198179
$3,938.06
in general payments reported to CMS, 2019-2025
40 companies · $562 in 2025
The $562 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $144 · 2021: $593 · 2022: $623 · 2023: $817 · 2024: $791 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.56 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,435.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $428.52 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $209.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $192.81 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $168.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $150.89 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.67 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $128.82 | 2022-2023 | Myrbetriq |
| Amgen INC. | $109.77 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $99.73 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.27 | 2021-2025 | |
| Medtronic, INC. | $56.24 | 2023-2024 | Mazor X System, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $55.17 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.41 | 2024-2025 | Caplyta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.